<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03455296</url>
  </required_header>
  <id_info>
    <org_study_id>Lactate</org_study_id>
    <nct_id>NCT03455296</nct_id>
  </id_info>
  <brief_title>Fluid Management Surgical Patients in Intensive Care Unit.</brief_title>
  <official_title>Fluid Management Guided With Lactate Clearance Versus Central Venous Oxygen Saturation Monitoring in Surgical Patients in Intensive Care Unit.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Hepatology &amp; Tropical Medicine Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Hepatology &amp; Tropical Medicine Research Institute</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate the efficacy of lactate clearance (LCR) versus central&#xD;
      venous oxygen saturation (ScVO2) to guide fluid management for post-operative patients in the&#xD;
      intensive care unit (ICU).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sixty patients will be randomly assigned in a 1:1 manner into two groups; (group A= thirty&#xD;
      patients = ScVO2) &amp; (group B = thirty patients =lactate clearance). Fluid therapy will be&#xD;
      initiated in each group with maintenance in the form of crystalloid e.g. Ringer or Ringer&#xD;
      acetate (in a dose of 30-35 ml/Kg/day) plus replacement with crystalloid e.g. Ringer, Ringer&#xD;
      acetate or saline 0.9%, 500 ml over 10-30 min. that will be administered in boluses [7]&#xD;
      guided by ScVO2with target value ≥ 70% versus lactate clearance (LCR) with target value ≤&#xD;
      2mmol/L (or decline ≥ 10%) by the end of the study in group A &amp; group B respectively with&#xD;
      close regular clinical monitoring/30min., CVP limits 12-16 cmH2O &amp; mean arterial pressure&#xD;
      (MAP) 65-90mmHg. Maintenance fluid without replacement will be initiated alone if ScVO2 or&#xD;
      lactate value normalized or are normal from the start.&#xD;
&#xD;
      All demographic data will be obtained including the patients' age, sex, body mass index&#xD;
      (BMI), associated co-morbidities (diabetes mellitus &amp;hypertension), Sequential Organ Failure&#xD;
      Assessment (SOFA) on admission &amp; discharge from ICU, duration of surgery, the type of&#xD;
      surgery, the amount of blood loss intraoperative, the amount of blood transfused&#xD;
      intraoperative, the need&amp;the amount of blood transfusion postoperative &amp; will be recorded.&#xD;
&#xD;
      Follow-up hemodynamics including the heart rate, mean arterial pressure (MAP), CVP, arterial&#xD;
      oxygen saturation (SaO2), urine volume, fluid balance, blood gases (base excess, PH), hypoxic&#xD;
      index (PaO2/FIO2 ratio) &amp; total fluid infused as a baseline then followed as required.&#xD;
      Monitoring of either lactate level or ScVO2 on admission followed and recorded at regular&#xD;
      intervals during treatment on 0, 2, 6, 12, 24 &amp; 48hours.&#xD;
&#xD;
      Laboratory investigations including the complete blood profile, prothrombin time, liver&#xD;
      functions, serum creatinine &amp; serum electrolytes will be assessed at randomization as a&#xD;
      baseline &amp; then will be recorded as required. Postoperative medical or surgical morbidities&#xD;
      will be followed during ICU &amp; hospital stay e.g. weight gain, impairment of hypoxic index&#xD;
      (P/F ratio), pulmonary edema, pleural effusion, need for mechanical ventilation, paralytic&#xD;
      ileus, renal impairment&amp; intra-abdominal bleeding.28-day mortality will be asked for &amp;&#xD;
      followed by calling the telephone number of the patient or one of his/her first-degree&#xD;
      relatives.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 1, 2018</start_date>
  <completion_date type="Actual">May 15, 2020</completion_date>
  <primary_completion_date type="Actual">February 15, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ICU stay</measure>
    <time_frame>2-5 days</time_frame>
    <description>Length of stay in days</description>
  </primary_outcome>
  <primary_outcome>
    <measure>medical complications</measure>
    <time_frame>2-5 days</time_frame>
    <description>notice any medical complications e.g.infections, pulmonary edema, pleural effusion, need mechanical ventilation, renal impairment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>surgical complications</measure>
    <time_frame>2-5 days</time_frame>
    <description>notice any surgical complications e.g. wound dehisence, intrabdominal bleeding, ileus</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>cost of each method</measure>
    <time_frame>within 48 hours</time_frame>
    <description>cost for fluids given &amp; the method used ScVO2 or Lactate measurements</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hospital stay</measure>
    <time_frame>2-5 days</time_frame>
    <description>length of stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mortality</measure>
    <time_frame>28 day</time_frame>
    <description>28 day mortality</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Post Operative Fluid Management</condition>
  <arm_group>
    <arm_group_label>central venous oxygen saturation ScVO2 normalization</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fluid therapy is initiated with maintenance fluid (Ringer or Ringer acetate) plus replacement with crystalloids (Ringer, Ringer acetate or saline 0.9%) 500ml / 30 min. guided by ScVO2with target value ≥ 70%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lactate clearance</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fluid therapy is initiated with maintenance fluid (Ringer or Ringer acetate) plus replacement with crystalloids 500ml / 30 min. guided by lactate clearance (LCR) with target value ≤ 2mmol/L (or decline ≥ 10%) by the end of the study</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>fluid therapy; crystalloid</intervention_name>
    <description>maintenance fluid e.g. Ringer or Ringer acetate plus replacement fluid with crystalloids e.g. Ringer,or Ringer acetate or saline 0.9%, 500ml / 30 min. guided by ScVO2 with target value ≥ 70% versus lactate clearance (LCR) with target value ≤ 2mmol/L (or decline ≥ 10%) by the end of the study in group A &amp; group B respectively. Maintenance fluid without replacement will be initiated if ScVO2 or lactate value normalized.</description>
    <arm_group_label>Lactate clearance</arm_group_label>
    <arm_group_label>central venous oxygen saturation ScVO2 normalization</arm_group_label>
    <other_name>Ringeror Ringer acetate or saline 0.9%</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients who are admitted to the intensive care unit of National Hepatology &amp; Tropical&#xD;
             Medicine Research Institute (NHTMRI) post intra-abdominal surgical intervention.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients will be excluded from the study if they have severe liver impairment&#xD;
             (child-Pugh C15), septic shock or hemodynamic instability requiring high dose&#xD;
             circulatory support e.g. &gt; 2ug/min noradrenaline as it will impair lactate clearance&#xD;
             &amp;/or central venous oxygen saturation normalization, advanced heart failure, central&#xD;
             venous pressure (CVP) ≥ 18cmH2O as it will limit fluid therapy, severe hypothermia (&lt;&#xD;
             28◦ C) as it will induce lactate production.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>NHTMRI</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>January 3, 2018</study_first_submitted>
  <study_first_submitted_qc>February 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 6, 2018</study_first_posted>
  <last_update_submitted>March 17, 2021</last_update_submitted>
  <last_update_submitted_qc>March 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Hepatology &amp; Tropical Medicine Research Institute</investigator_affiliation>
    <investigator_full_name>ICU</investigator_full_name>
    <investigator_title>Consultant of Intensive care medicine, Ph D</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

